Navigation Links
John Theurer Cancer Center first in New Jersey to offer complete capabilities of Provenge
Date:4/4/2011

HACKENSACK, N.J. (April 4, 2011) The John Theurer Cancer Center at Hackensack University Medical is the only cancer center in New Jersey where advanced prostate cancer patients can receive a cell collection process and infusion of Provenge (Sipuleucel-T). Now, patients can find the complete capabilities of this breakthrough immunotherapy in one center led by one physician.

"We are now able to provide patients with care that is not only innovative for improved outcomes, but convenient and more personal," said Robert Alter, M.D., Co-Chief, Urologic Oncology at the John Theurer Cancer Center. "Throughout the Provenge delivery process, patients are treated by a single team of our expert staff, allowing for a more intimate, comforting course of treatment."

Provenge is the first autologous cellular immunotherapy available for the treatment of advanced prostate cancer, meaning it is designed to use cells from a patient's own immune system to identify and target prostate cancer. The John Theurer Cancer Center participated in the Provenge clinical trials, and began prescribing and infusing patients when the treatment was approved in June 2010. This February, the John Theurer Cancer Center received approval by Provenge manufacturer, Dendreon, to conduct leukapheresis, a cell collection process vital for the development of the immunotherapy.

"Provenge is another example of the cutting-edge treatments we provide our patients at the John Theurer Cancer Center," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer and Professor and Vice President of Cancer Services at the John Theurer Cancer Center. "We strive to deliver patients with the latest treatment options and state-of-the-art technology in order to deliver exceptional care."

Provenge treatment at the John Theurer Cancer Center begins with leukapheresis, a cell collection process administered by a clinical assistant. The patient's cells are sent to a Provenge manufacturing facility, where they are combined with a protein that is found in most prostate cancers linked to an immune stimulating agent. The dose of Provenge is then sent back to the cancer center for infusion. This whole process is performed three times over approximately six weeks for complete treatment.


'/>"/>

Contact: Jaymie DeGaetano
jaymie.degaetano@widmeyer.com
646-213-7243
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. The MMRF and John Theurer Cancer Center to host patient symposium
2. John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques
3. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
4. Oncology basic research director at John Theurer Cancer Center continues transplantation research
5. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
6. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
7. John Theurer Cancer Center to present innovative research at 2 surgical meetings
8. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
9. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
10. The John Theurer Cancer Center recognizes medical physics team for safety track record
11. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 2017 , ... “The Inn at the Mill”: a story of love and redemption, hope ... become happy and content. , “The Inn at the Mill” is the creation of ... and Vermont and is now living in Berks County on Crow Hill. The ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating ... of Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the ... years, a preacher for over nineteen, a pastor for over fifteen years. He is ...
(Date:1/22/2017)... Viejo, California (PRWEB) , ... January 22, 2017 , ... ... Photo Cloud to create a beautiful 3D slideshow with complete ease," said Christina Austin ... the Generators browser to place in the FCPX timeline. Presets include scenes ...
(Date:1/21/2017)... California (PRWEB) , ... January 21, 2017 , ... "ProDOF is the perfect set of ... subject to another subject in a scene," said Christina Austin - CEO of Pixel Film ... given scene. Easily create the illusion of a DSLR racking focus from one area ...
(Date:1/21/2017)... ... 21, 2017 , ... Northern California Medical Associates (NCMA) is ... multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient surgery, clinical ... this excellent dermatology practice to our group’s medical services,” explains NCMA CEO, Ruth ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017 A new Transparency Market Research ... was valued at US$0.53 bn in 2013 and is predicted to ... CAGR between 2014 and 2022. The title of the report is ... Share, Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred ...
(Date:1/23/2017)... SAN FRANCISCO , January 23, 2017 The global  ... USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated ... and psychotherapies has resulted in the declining demand for antidepressants in the recent ... ... Grand View Research Logo ...
(Date:1/23/2017)... SAN DIEGO , 23. Januar 2017  ResMed ... China ) und 3B Medical ( Winter ... sich auf eine Vereinbarung über die Beilegung aller globalen ... ist der Verkauf ihrer bestehenden Produkte im ... eine einmalige Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology: